Muromonab-CD3 (also known as OKT3) is Anti-CD3 mAbs. OKT3 binds to CD3 associated with T-cell receptor, leading to initial activation of T-lymphocytes and cytokine release, followed by blockade of the function, lysis, and T-cell depletion. Cytokine release syndrome (short-term physiologic changes) is the most common adverse effect of OKT3 resembles a systemic inflammatory response, including high fever, hypotension, chills, nausea, vomiting, diarrhea, dyspnea and even pulmonary edema. However, aseptic meningitis or intragraft thrombosis are rare adverse events. Muromonab-CD3 is now rarely used in transplantation.
